Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Trial Profile

Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Haemolytic uraemic syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 08 Feb 2018 According to an Alexion Pharmaceuticals media release, data from this study is expected in the fourth quarter of 2018. And enrollment is expected to be complete in the second quarter of 2018
    • 30 Jan 2018 Planned End Date changed from 1 Dec 2019 to 1 Nov 2020.
    • 30 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top